Filing Details

Accession Number:
0000899243-21-002076
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-14 17:51:02
Reporting Period:
2021-01-12
Accepted Time:
2021-01-14 17:51:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1789972 Cullinan Management Inc. CGEM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1134655 Ansbert Gadicke C/o Mpm Asset Management Llc
450 Kendall Street
Cambridge MA 02142
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-07 281,268 $0.00 281,268 No 4 J Direct
Common Stock Acquisiton 2021-01-12 1,136,525 $0.00 1,136,525 No 4 C Indirect See footnotes
Common Stock Acquisiton 2021-01-12 3,551,640 $0.00 4,688,165 No 4 C Indirect See footnotes
Common Stock Acquisiton 2021-01-12 2,276,692 $0.00 6,964,857 No 4 C Indirect See footnotes
Common Stock Acquisiton 2021-01-12 649,030 $0.00 7,613,887 No 4 C Indirect See footnotes
Common Stock Acquisiton 2021-01-12 300,000 $21.00 7,913,887 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 J Direct
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series Seed Convertible Preferred Stock Acquisiton 2021-01-07 1,136,525 $0.00 1,136,525 $0.00
Common Stock Series A Convertible Preferred Stock Acquisiton 2021-01-07 3,551,640 $0.00 3,551,640 $0.00
Common Stock Series B Convertible Preferred Stock Acquisiton 2021-01-07 2,276,692 $0.00 2,276,692 $0.00
Common Stock Series C Convertible Preferred Stock Acquisiton 2021-01-07 649,030 $0.00 649,030 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2021-01-07 262,114 $0.00 262,114 $4.30
Common Stock Stock Option (Right to Buy) Acquisiton 2021-01-07 88,824 $0.00 88,824 $4.30
Common Stock Series Seed Convertible Preferred Stock Disposition 2021-01-12 1,136,525 $0.00 1,136,525 $0.00
Common Stock Series A Convertible Preferred Stock Disposition 2021-01-12 3,551,640 $0.00 3,551,640 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2021-01-12 2,276,692 $0.00 2,276,692 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2021-01-12 649,030 $0.00 649,030 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,136,525 No 4 J Indirect
3,551,640 No 4 J Indirect
2,276,692 No 4 J Indirect
649,030 No 4 J Indirect
262,114 2030-10-28 No 4 J Direct
88,824 2030-10-28 No 4 J Direct
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the "Preferred Stock") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
  2. 25% of the shares vested on March 8, 2018, and the remaining shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
  3. In connection with the Issuer's initial public offering, on January 7, 2021, these securities of the Issuer were received pursuant to a corporate reorganization.
  4. These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC.
  5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  6. On January 12, 2021, OIF purchased 300,000 shares of Common Stock of the Issuer at a price of $21.00 per share pursuant to the Issuer's initial public offering.